Christian Gilfrich, Matthias May, Christian Gratzke, Claus Fahlenbrach, Christian Günster, Elke Jeschke, Gralf Popken, Jan Roigas, Jens-Uwe Stolzenburg, Hanna Leicht
{"title":"经尿道前列腺切除术和钬激光前列腺切除术后良性前列腺梗阻的再手术：一项超过33000例原发性手术干预的3年随访研究。","authors":"Christian Gilfrich, Matthias May, Christian Gratzke, Claus Fahlenbrach, Christian Günster, Elke Jeschke, Gralf Popken, Jan Roigas, Jens-Uwe Stolzenburg, Hanna Leicht","doi":"10.1016/j.euf.2025.02.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Large-scale studies comparing the efficacy of transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) are scarce, particularly concerning the influence of hospital volume. This study aims to evaluate the 3-yr reoperation risk for benign prostatic obstruction (BPO) following TURP versus HoLEP, adjusted for procedure-specific annual hospital volume.</p><p><strong>Methods: </strong>This retrospective study is based on pseudonymized data from the German local health care funds (Allgemeine Ortskrankenkassen [AOK]) for BPO patients who underwent TURP (n = 29 790) or HoLEP (n = 3330) between 2017 and 2019. Three-year reoperation risk was assessed using the Kaplan-Meier (KM) method and a multivariate Cox proportional-hazard model adjusted for comorbidities.</p><p><strong>Key findings and limitations: </strong>The unadjusted KM survival rate without reoperation was 93.5% (95% confidence interval [CI]: 93.2-93.7%) after TURP compared with 97.0% after HoLEP (96.3-97.5%; p < 0.001). In a multivariate analysis, HoLEP was associated with a lower reoperation risk than TURP (hazard ratio [HR] ranging from 0.23 [95% CI: 0.14-0.38] to 0.65 [95% CI: 0.42-0.98], depending on hospital volume). However, HoLEP hospital volumes of one to 49 (HR 2.74, 95% CI: 1.44-5.22) and 50-99 (HR 2.36, 95% CI: 1.27-4.39) cases annually were linked to a higher risk of reoperation than volumes of ≥250 cases, while no such volume effect was observed for TURP. The limitations of this study are the following: it is a retrospective, nonrandomized study and it lacks clinical information (eg, prostate volume and functional results).</p><p><strong>Conclusions and clinical implications: </strong>HoLEP demonstrates a significantly reduced reoperation risk for BPO compared with TURP at intermediate follow-up, with dependence on procedure-specific hospital volume, which is not evident for TURP.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reoperation for Benign Prostatic Obstruction Following Transurethral Resection and Holmium Laser Enucleation of the Prostate: A 3-year Follow-up Study of Over 33 000 Primary Surgical Interventions.\",\"authors\":\"Christian Gilfrich, Matthias May, Christian Gratzke, Claus Fahlenbrach, Christian Günster, Elke Jeschke, Gralf Popken, Jan Roigas, Jens-Uwe Stolzenburg, Hanna Leicht\",\"doi\":\"10.1016/j.euf.2025.02.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Large-scale studies comparing the efficacy of transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) are scarce, particularly concerning the influence of hospital volume. This study aims to evaluate the 3-yr reoperation risk for benign prostatic obstruction (BPO) following TURP versus HoLEP, adjusted for procedure-specific annual hospital volume.</p><p><strong>Methods: </strong>This retrospective study is based on pseudonymized data from the German local health care funds (Allgemeine Ortskrankenkassen [AOK]) for BPO patients who underwent TURP (n = 29 790) or HoLEP (n = 3330) between 2017 and 2019. Three-year reoperation risk was assessed using the Kaplan-Meier (KM) method and a multivariate Cox proportional-hazard model adjusted for comorbidities.</p><p><strong>Key findings and limitations: </strong>The unadjusted KM survival rate without reoperation was 93.5% (95% confidence interval [CI]: 93.2-93.7%) after TURP compared with 97.0% after HoLEP (96.3-97.5%; p < 0.001). In a multivariate analysis, HoLEP was associated with a lower reoperation risk than TURP (hazard ratio [HR] ranging from 0.23 [95% CI: 0.14-0.38] to 0.65 [95% CI: 0.42-0.98], depending on hospital volume). However, HoLEP hospital volumes of one to 49 (HR 2.74, 95% CI: 1.44-5.22) and 50-99 (HR 2.36, 95% CI: 1.27-4.39) cases annually were linked to a higher risk of reoperation than volumes of ≥250 cases, while no such volume effect was observed for TURP. The limitations of this study are the following: it is a retrospective, nonrandomized study and it lacks clinical information (eg, prostate volume and functional results).</p><p><strong>Conclusions and clinical implications: </strong>HoLEP demonstrates a significantly reduced reoperation risk for BPO compared with TURP at intermediate follow-up, with dependence on procedure-specific hospital volume, which is not evident for TURP.</p>\",\"PeriodicalId\":12160,\"journal\":{\"name\":\"European urology focus\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2025.02.017\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2025.02.017","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Reoperation for Benign Prostatic Obstruction Following Transurethral Resection and Holmium Laser Enucleation of the Prostate: A 3-year Follow-up Study of Over 33 000 Primary Surgical Interventions.
Background and objective: Large-scale studies comparing the efficacy of transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) are scarce, particularly concerning the influence of hospital volume. This study aims to evaluate the 3-yr reoperation risk for benign prostatic obstruction (BPO) following TURP versus HoLEP, adjusted for procedure-specific annual hospital volume.
Methods: This retrospective study is based on pseudonymized data from the German local health care funds (Allgemeine Ortskrankenkassen [AOK]) for BPO patients who underwent TURP (n = 29 790) or HoLEP (n = 3330) between 2017 and 2019. Three-year reoperation risk was assessed using the Kaplan-Meier (KM) method and a multivariate Cox proportional-hazard model adjusted for comorbidities.
Key findings and limitations: The unadjusted KM survival rate without reoperation was 93.5% (95% confidence interval [CI]: 93.2-93.7%) after TURP compared with 97.0% after HoLEP (96.3-97.5%; p < 0.001). In a multivariate analysis, HoLEP was associated with a lower reoperation risk than TURP (hazard ratio [HR] ranging from 0.23 [95% CI: 0.14-0.38] to 0.65 [95% CI: 0.42-0.98], depending on hospital volume). However, HoLEP hospital volumes of one to 49 (HR 2.74, 95% CI: 1.44-5.22) and 50-99 (HR 2.36, 95% CI: 1.27-4.39) cases annually were linked to a higher risk of reoperation than volumes of ≥250 cases, while no such volume effect was observed for TURP. The limitations of this study are the following: it is a retrospective, nonrandomized study and it lacks clinical information (eg, prostate volume and functional results).
Conclusions and clinical implications: HoLEP demonstrates a significantly reduced reoperation risk for BPO compared with TURP at intermediate follow-up, with dependence on procedure-specific hospital volume, which is not evident for TURP.
期刊介绍：
European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU).
EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
